Published on
April 15, 2021

Revive Reschedules Annual and Special Meeting and Provides Dial-In Information

TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to announce that, further to its press release of April 12, 2021, its Annual and Special Meeting (the “Meeting”) has been rescheduled to take place on Monday April 19, 2021 at 11:00 a.m. E.D.T. Shareholders and proxyholders may access the Meeting via teleconference by dialing 1-855-327-6838 from Canada or the United States. Due to the high turnout on Monday April 12, 2021, shareholders are encouraged to call into the Meeting at 10:45 a.m. E.D.T. The Meeting will commence promptly at 11:00 a.m.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit

For more information please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.

Tel: 1 888 901 0036Email:

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.